Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a high risk of transmission in close-contact indoor settings, which may include households. Prior studies have found a wide range of household secondary attack rates and may contain biases due to simplifying assumptions about transmission variability and test accuracy.
Methods We compiled serological SARS-CoV-2 antibody test data and prior PCR test reporting from members of more than 9000 Utah households. We paired these data with a probabilistic model of household importation and transmission. We calculated a maximum likelihood estimate of the importation probability, mean and variability of household transmission probability, and sensitivity and specificity of test data. Given our household transmission estimates, we estimated the threshold of non-household transmission required for epidemic growth in the population.
Results We estimated that individuals in our study households had a 0.38% (95% CI 0.30% – 0.48%) chance of acquiring SARS-CoV-2 infection outside their household. Our household secondary attack rate estimate was 35% (26% – 47%), substantially higher than the crude estimate of 15% unadjusted for imperfect serological test specificity and other factors. We found evidence for high variability in individual transmissibility, with higher probability of no transmissions or many transmissions compared to standard models. With household transmission at our estimates, the average number of non-household transmissions per case must be kept below 0.40 (0.32 – 0.51) to avoid continued growth of the Utah epidemic.
Conclusions Our findings suggest that crude estimates of household secondary attack rate based on serology data without accounting for false positive tests may underestimate the true average transmissibility, even when test specificity is high. Our finding of potential high variability (overdispersion) in transmissibility of infected individuals is consistent with characterizing SARS-CoV-2 transmission being largely driven by superspreading from a minority of infected individuals. Mitigation efforts targeting large households and other locations where many people congregate indoors might curb continued spread of the virus.
Competing Interest Statement
Dr. Toth and Dr. Samore report grants from Pfizer Inc., outside the submitted work. Dr. Keegan reports grants from Pfizer Inc. and Becton, Dickinson and Company, outside the submitted work. Dr. Greene reports grants from AstraZeneca, Boehringer Ingelheim, CSL, and Vertex Pharmaceuticals and personal fees from Janssen Pharmaceuticals, Pfizer Inc., Novartis, and AstraZeneca, outside the submitted work. Other authors declare no competing interest.
Funding Statement
The data analyzed in this work were collected with funding from the State of Utah. Authors performing mathematical modeling were supported by grants from the Centers for Disease Control and Prevention (U01CK000585) and Department of Veterans Affairs (I50HX001240).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The surveillance project that produced the data analyzed in this manuscript was designated by the University of Utah Institutional Review Board as non-research public health surveillance (IRB_00132598).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data necessary to reproduce the results in the manuscript are publicly available.
